100 related articles for article (PubMed ID: 30617666)
1. Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review.
Afari ME; Aoun J; Khare S; Tsao L
Heart Fail Rev; 2019 May; 24(3):309-313. PubMed ID: 30617666
[TBL] [Abstract][Full Text] [Related]
2. Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians.
Vazir A; Kapelios CJ; Agaoglu E; Metra M; Lopatin Y; Seferovic P; Mullens W; Filippatos G; Rosano G; Coats AJS; Chioncel O
Eur J Heart Fail; 2023 Sep; 25(9):1555-1570. PubMed ID: 37565377
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous furosemide patch: heart failure decongestion 'from the comfort of your home'.
Dimitriadis K; Pyrpyris N; Tsioufis K
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):259-260. PubMed ID: 38289722
[No Abstract] [Full Text] [Related]
4. A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure.
Nwosu C; Mezue K; Bhagatwala K; Ezema N
Curr Cardiol Rev; 2016; 12(4):311-317. PubMed ID: 26926295
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of initial intravenous diuretic dose in acute heart failure.
Bendoudouch H; El Boussaadani B; Hara L; Ech-Chenbouli A; Raissouni Z
Eur J Intern Med; 2024 Jun; 124():134-135. PubMed ID: 38378344
[No Abstract] [Full Text] [Related]
6. Intravenous diuretic day-care treatment for patients with heart failure.
Banerjee P; Tanner G; Williams L
Clin Med (Lond); 2012 Apr; 12(2):133-6. PubMed ID: 22586787
[TBL] [Abstract][Full Text] [Related]
7. Reply: subcutaneous furosemide patch: heart failure decongestion 'from the comfort of your home'.
Osmanska J; Petrie MC; Campbell RT
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):261-262. PubMed ID: 38366161
[No Abstract] [Full Text] [Related]
8. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies.
Osmanska J; Brooksbank K; Docherty KF; Robertson S; Wetherall K; McConnachie A; Hu J; Gardner RS; Clark AL; Squire IB; Kalra PR; Jhund PS; Muntendam P; McMurray JJV; Petrie MC; Campbell RT
Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):35-44. PubMed ID: 37804170
[TBL] [Abstract][Full Text] [Related]
9. A novel opportunity to improve heart failure care: focusing on subcutaneous furosemide.
Khan WJ; Arriola-Montenegro J; Mutschler MS; Bensimhon D; Halmosi R; Toth K; Alexy T
Heart Fail Rev; 2023 Nov; 28(6):1315-1323. PubMed ID: 37439967
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous Furosemide: A Novel to Euvolemia.
Cheikhali R; Kalish C; Maksymiuk V; Nasereldin M; Bahl S; Frishman WH; Aronow WS; Pan S
Cardiol Rev; 2024 Mar; ():. PubMed ID: 38520337
[TBL] [Abstract][Full Text] [Related]
11. Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide.
Andre AD; Mohr JF; Cornelius BW; Goodwin MM; Whitaker CP; Patel BH; Huckleberry JA; Hassman MD
Med Devices (Auckl); 2024; 17():229-235. PubMed ID: 38948076
[TBL] [Abstract][Full Text] [Related]
12. Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature.
Wierda E; Dickhoff C; Handoko ML; Oosterom L; Kok WE; de Rover Y; de Mol BAJM; van Heerebeek L; Schroeder-Tanka JM
ESC Heart Fail; 2020 Jun; 7(3):892-902. PubMed ID: 32159279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study.
Besche B; Blondel T; Guillot E; Garelli-Paar C; Oyama MA
J Vet Intern Med; 2020 Sep; 34(5):1746-1758. PubMed ID: 32767627
[TBL] [Abstract][Full Text] [Related]
14. A reply to "Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial".
Shetty AH; Shetty HB
Clin Res Cardiol; 2020 Apr; 109(4):523-524. PubMed ID: 31605192
[No Abstract] [Full Text] [Related]
15. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.
Abraham B; Megaly M; Sous M; Fransawyalkomos M; Saad M; Fraser R; Topf J; Goldsmith S; Simegn M; Bart B; Azzo Z; Mesiha N; Sharma R
Am J Cardiol; 2020 Jan; 125(1):92-99. PubMed ID: 31699358
[TBL] [Abstract][Full Text] [Related]
16. Furosemide in end-stage heart failure: community subcutaneous infusions.
Brown A; Westley K; Robson J; Armstrong L; Matthews I; Runnett C; Ripley D; Thomas H
BMJ Support Palliat Care; 2022 Dec; 12(e6):e763-e766. PubMed ID: 32647034
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous furosemide in advanced heart failure: service improvement project.
Birch F; Boam E; Parsons S; Ghosh J; Johnson MJ
BMJ Support Palliat Care; 2023 Mar; 13(1):112-116. PubMed ID: 33452045
[TBL] [Abstract][Full Text] [Related]
18. Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs.
Potter BM; Ames MK; Hess A; Poglitsch M
J Vet Cardiol; 2019 Dec; 26():51-62. PubMed ID: 31809955
[TBL] [Abstract][Full Text] [Related]
19. Use of community-based subcutaneous furosemide in advanced heart failure: experience of a new service in the north-east of England.
Brown A; Robson J; Armstrong L; Matthews I; Runnett C; Thomas H
Future Healthc J; 2019 Mar; 6(Suppl 1):19. PubMed ID: 31363544
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
